Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy of Non-Hodgkin’s Lymphoma
Oncology Drug Advisory Committee Meeting September 11, 2001
ODAC Presentation *
Next slide
Back to first slide
View graphic version